Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR).

被引：0
|
作者：
Piazza, R
Magistroni, V
Tornaghi, L
Andreoni, F
Bungaro, S
Cazzaniga, G
Biondi, A
Pogliani, E
Varella-Garcia, M
Corneo, G
Gambacorti-Passerini, C
机构：
[1] Natl Canc Inst, I-20133 Milan, Italy
[2] Univ Milano Bicocca, Osped San Gerardo, Monza, Italy
[3] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4996
引用
收藏
页码：319B / 319B
页数：1
相关论文
共 50 条
  • [41] Probability and impact of obtaining a cytogenetic response to imatinib as initial therapy for chronic myeloid leukemia (CML) in chronic phase.
    Druker, BJ
    Gathmann, I
    Bolton, AE
    Larson, RA
    BLOOD, 2003, 102 (11) : 182A - 182A
  • [42] Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).
    Shah, Neil
    Bahceci, Erkut
    Lambert, Alexandre
    Ploughman, Lynn
    Radich, Jerald
    BLOOD, 2009, 114 (22) : 460 - 460
  • [43] Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
    Cortes, Jorge E.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Quintas-Cardama, Alfonso
    Ravandi, Farhad
    Gachimova, Evguenia
    Estrov, Zeev
    Jabbour, Elias
    O'Brien, Susan
    Kantarjian, Hagop
    BLOOD, 2013, 122 (21)
  • [44] Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Jain, Preetesh
    Kantarjian, Hagop M.
    Jabbour, Elias
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Gachimova, Evguenia
    Ferrajoli, Alessandra
    Kornblau, Steven M.
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [45] Dasatinib as initial therapy for patients with chronic myeloid leukemia (CML) in early chronic phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop
    O'Brien, Susan
    Luthra, Raja
    Jabbour, Elias
    Quintas-Cardama, Aflonso
    Borthakur, Gautam
    Ravandi, Farhad
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge
    CANCER RESEARCH, 2011, 71
  • [46] Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM)
    Cortes, J. E.
    Kantarjian, H.
    Bruemmendorf, T.
    Khoury, H. J.
    Kim, D.
    Turkina, A.
    Volkert, A.
    Wang, J.
    Arkin, S.
    Gambacorti-Passerini, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] A phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (Pts) with chronic myeloid leukemia (CML) in chronic phase (CP) who failed IM therapy.
    Cortes, J
    Garcia-Manero, G
    O'Brien, S
    Hernandez, I
    Rackoff, W
    Faderl, S
    Thomas, D
    Ferrajoli, A
    Talpaz, M
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 289A - 289A
  • [48] Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response
    Iurlo, Alessandra
    Latagliata, Roberto
    Bucelli, Cristina
    Ferrero, Dario
    Castagnetti, Fausto
    Breccia, Massimo
    Abruzzese, Elisabetta
    Cattaneo, Daniele
    Fava, Carmen
    Gozzini, Antonella
    Annunziata, Mario
    Tiribelli, Mario
    Pregno, Patrizia
    Stagno, Fabio
    Vigneri, Paolo
    Cavazzini, Francesco
    Binotto, Gianni
    Mansueto, Giovanna
    Russo, Sabina
    Falzetti, Franca
    Montefusco, Enrico
    Gugliotta, Gabriele
    Gasbarrino, Cristiana
    D'Addosio, Ada
    Cortesi, Laura
    Cedrone, Michele
    Rossi, Antonella Russo
    Avanzini, Paolo
    Endri, Mauro
    Spadea, Antonio
    Celesti, Francesca
    Giglio, Gianfranco
    Isidori, Alessandro
    Crugnola, Monica
    Calistri, Elisabetta
    Sora, Federica
    Rege-Cambrin, Giovanna
    Sica, Simona
    Luciano, Luigia
    Orlandi, Ester Maria
    Bocchia, Monica
    Tettamanti, Mauro
    Alimena, Giuliana
    Saglio, Giuseppe
    Rosti, Gianantonio
    Nobili, Alessandro
    Mannucci, Pier Mannuccio
    Cortelezzi, Agostino
    BLOOD, 2015, 126 (23)
  • [49] Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy
    Alimena, Giuliana
    Breccia, Massimo
    Latagliata, Roberto
    Carmosino, Ida
    Russo, Eleonora
    Biondo, Francesca
    Diverio, Daniela
    Mancini, Marco
    Nanni, Mauro
    Mandelli, Franco
    CANCER, 2006, 107 (05) : 1008 - 1013
  • [50] Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Baccarani, Michele
    de Coutre, Philipp D.
    Haque, Ariful
    Gallagher, Neil J.
    Cortes, Jorge
    Giles, Francis
    BLOOD, 2008, 112 (11) : 1103 - 1103
12345